The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity - Oelze, M; Kroller-Schon, S; Welschof, P (PLoS One, 2014)
et al.